The natural polyphenol fisetin in atherosclerosis prevention: a mechanistic review

Author:

Yu Wei123ORCID,Zhao Yaping4,Ilyas Iqra4,Wang Li5,Little Peter J6ORCID,Xu Suowen4ORCID

Affiliation:

1. School of Materials Science and Engineering, Hefei University of Technology , Hefei, Anhui, 230009 , China

2. Anhui Renovo Pharmaceutical Co., Ltd , Hefei, Anhui, 230001 , China

3. Anhui Guozheng Pharmaceutical Co., Ltd , Hefei, Anhui, 230041 , China

4. Department of Endocrinology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, 230001 , China

5. Department of Biomedical Sciences, City University of Hong Kong , Hong Kong Special Administrative Region , China

6. Department of Pharmacy, Guangzhou Xinhua University , No. 721, Guangshan Road 1, Tianhe District, Guangzhou, 510520 , China

Abstract

Abstract The incidence and mortality rate of atherosclerotic cardiovascular disease (ASCVD) is increasing yearly worldwide. Recently, a growing body of evidence has unveiled the anti-atherosclerotic properties of fisetin, a natural polyphenol compound. In this article, we reviewed the pharmacologic actions of fisetin on experimental atherosclerosis and its protective effects on disease-relevant cell types such as endothelial cells, macrophages, vascular smooth muscle cells, and platelets. Based on its profound cardiovascular actions, fisetin holds potential for clinical translation and could be developed as a potential therapeutic option for atherosclerosis and its related complications. Large-scale randomized clinical trials are warranted to ascertain the safety and efficacy of fisetin in patients with or high risk for ASCVD.

Funder

Anhui Provincial Key Research and Development Program

Publisher

Oxford University Press (OUP)

Reference176 articles.

1. NCDs: a challenge to sustainable human development;Clark;Lancet,2013

2. Cardiovascular disease epidemiology in Asia: an overview;Ohira;Circ J,2013

3. A versatile big data health system for Australia: driving improvements in cardiovascular health;Paige;Heart Lung Circ,2021

4. A unified national cardiovascular disease (CVD) risk generator is required to address equity in the management of CVD risk in clinical practice in New Zealand;Kerr;N Z Med J,2019

5. Added sugar intake and cardiovascular diseases mortality among US adults;Yang;JAMA Intern Med,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3